Aerie Pharmaceuticals reported $-18137000 in Operating Profit for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Operating Profit Change
Aerie Pharmaceuticals AERI:US $ -18.14M 15.51M
Alimera Sciences ALIM:US $ -1.97M 2.17M
Amarin AMRN:US $ -62.83M 34.52M
Bluebird Bio BLUE:US $ -107.4M 12.95M
Cara Therapeutics CARA:US $ -4472000 23.44M
Coherus Biosciences CHRS:US $ -44.01M 43.13M
Horizon Pharma HZNP:US $ 88.56M 105.76M
Insmed INSM:US $ -88316000 1.52M
Merk MRK:US $ 4927M 642M
Mirati Therapeutics MRTX:US $ -177.2M 7.01M
Novartis NOVN:VX 2.23B 624M
Ophthotech OPHT:US $ -49.75M 15.08M
Pacira Pharmaceuticals PCRX:US $ 31.24M 13.84M
Regeneron Pharmaceuticals REGN:US $ 1109.9M 148.6M
Revance Therapeutics RVNC:US $ -57842000 4.38M
Supernus Pharmaceuticals SUPN:US $ 11.35M 9.38M
Teva Pharmaceutical Industries TEVA:US $ -949M 236M
Valeant Pharmaceuticals VRX:CN $ 352.69M 67.69M
Zoetis ZTS:US $ 670M 57M